Alliance for Pandemic Preparedness

December 8, 2020

Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Category:

Topic:

Keywords (Tags):

In a US household-randomized, double-blind, placebo-controlled trial among PCR-negative close contacts of persons with confirmed SARS-CoV-2 infection (n=689), no difference in SARS-CoV-2 acquisition by day 14 was observed between those receiving hydroxychloroquine post-exposure prophylaxis or placebo (HR = 1.10, 95% CI = 0.73-1.66). More participants in the hydroxychloroquine group experienced adverse events, including gastrointestinal symptoms and rash, compared to the control group (16.2% vs 10.9%, p = 0.026).

Barnabas et al. (Dec 8, 2020). Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Annals of Internal Medicine. https://doi.org/10.7326/M20-6519